Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND De-escalation from broad-spectrum to narrow-spectrum antibiotics is considered an important measure to reduce the selective pressure of antibiotics, but a scarcity of adequate evidence is a barrier to its implementation. We aimed to determine whether de-escalation from an antipseudomonal β-lactam to a narrower-spectrum drug was non-inferior to continuing the antipseudomonal drug in patients with Enterobacterales bacteraemia. METHODS An open-label, pragmatic, randomised trial was performed in 21 Spanish hospitals. Patients with bacteraemia caused by Enterobacterales susceptible to one of the de-escalation options and treated empirically with an antipseudomonal β-lactam were eligible. Patients were randomly assigned (1:1; stratified by urinary source) to de-escalate to ampicillin, trimethoprim-sulfamethoxazole (urinary tract infections only), cefuroxime, cefotaxime or ceftriaxone, amoxicillin-clavulanic acid, ciprofloxacin, or ertapenem in that order according to susceptibility (de-escalation group), or to continue with the empiric antipseudomonal β-lactam (control group). Oral switching was allowed in both groups. The primary outcome was clinical cure 3-5 days after end of treatment in the modified intention-to-treat (mITT) population, formed of patients who received at least one dose of study drug. Safety was assessed in all participants. Non-inferiority was declared when the lower bound of the 95% CI of the absolute difference in cure rate was above the -10% non-inferiority margin. This trial is registered with EudraCT (2015-004219-19) and ClinicalTrials.gov (NCT02795949) and is complete. FINDINGS 2030 patients were screened between Oct 5, 2016, and Jan 23, 2020, of whom 171 were randomly assigned to the de-escalation group and 173 to the control group. 164 (50%) patients in the de-escalation group and 167 (50%) in the control group were included in the mITT population. 148 (90%) patients in the de-escalation group and 148 (89%) in the control group had clinical cure (risk difference 1·6 percentage points, 95% CI -5·0 to 8·2). The number of adverse events reported was 219 in the de-escalation group and 175 in the control group, of these, 53 (24%) in the de-escalation group and 56 (32%) in the control group were considered severe. Seven (5%) of 164 patients in the de-escalation group and nine (6%) of 167 patients in the control group died during the 60-day follow-up. There were no treatment-related deaths. INTERPRETATION De-escalation from an antipseudomonal β-lactam in Enterobacterales bacteraemia following a predefined rule was non-inferior to continuing the empiric antipseudomonal drug. These results support de-escalation in this setting. FUNDING Plan Nacional de I+D+i 2013-2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases; Spanish Clinical Research and Clinical Trials Platform, co-financed by the EU; European Development Regional Fund "A way to achieve Europe", Operative Program Intelligence Growth 2014-2020.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005337 · Cited by 2,935
Piaggio, G., Elbourne, D. R., Pocock, S. J., Evans, S. J. W., Altman, D. G., & CONSORT Group, F. T. (2012) · JAMA · doi:10.1001/jama.2012.87802 · Cited by 2,428
Leone, M., Bechis, C., Baumstarck, K., Lefrant, J.-Y., Albanèse, J., Jaber, S., Lepape, A., Constantin, J.-M., Papazian, L., Bruder, N., et al. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3411-8 · Cited by 243
Tabah, A., Cotta, M. O., Garnacho-Montero, J., Schouten, J., Roberts, J. A., Lipman, J., Tacey, M., Timsit, J.-F., Leone, M., Zahar, J. R., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ1199 · Cited by 220
Moehring, R. W., Yarrington, M. E., Warren, B. G., Lokhnygina, Y., Atkinson, E., Bankston, A., Collucio, J., David, M. Z., Davis, A. E., Davis, J., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciac787 · Cited by 27
Cited by
Surviving Sepsis campaign: international guidelines for Management of Sepsis and Septic Shock 2026
Prescott, H. C., Antonelli, M., Alhazzani, W., Møller, M. H., Alshamsi, F., Azevedo, L. C. P., Belley-Cote, E., De Waele, J., Derde, L., Dionne, J. C., et al. (2026) · Critical Care Medicine · doi:10.1097/ccm.0000000000007075 · Cited by 117
Antibiotic De-escalation in adults hospitalized for community-onset Sepsis
Gupta, A. B., Heath, M., Walzl, E., Ratz, D., Munroe, E., Vaughn, V. M., Horowitz, J. K., Czilok, T., Petty, L. A., Gandhi, T. N., et al. (2026) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.6919 · Cited by 14
Antibiotic de-escalation practices in the intensive care unit: a multicenter observational study
Patanwala, A. E., Abu Sardaneh, A., Alffenaar, J.-W. C., Choo, C. L., Dey, A. L., Duffy, E. J., Green, S. E., Hills, T. E., Howle, L. M., Joseph, J. A., et al. (2025) · Annals of Pharmacotherapy · doi:10.1177/10600280241271223 · Cited by 2
Metadata
- Authors
- López-Cortés, L. E., Delgado-Valverde, M., Moreno-Mellado, E., Goikoetxea Aguirre, J., Guio Carrión, L., Blanco Vidal, M. J., López Soria, L. M., Pérez-Rodríguez, M. T., Martínez Lamas, L., Arnaiz de las Revillas, F., Armiñanzas, C., Ruiz de Alegría-Puig, C., Jiménez Aguilar, P., del Carmen Martínez-Rubio, M., Sáez-Bejar, C., de las Cuevas, C., Martín-Aspas, A., Galán, F., Yuste, J. R., Leiva-León, J., Bou, G., Capón González, P., Boix-Palop, L., Xercavins-Valls, M., Goenaga-Sánchez, M. Á., Anza, D. V., Castón, J. J., Rufián, M. R., Merino, E., Rodríguez, J. C., Loeches, B., Cuervo, G., Guerra Laso, J. M., Plata, A., Pérez Cortés, S., López Mato, P., Sierra Monzón, J. L., Rosso-Fernández, C., Bravo-Ferrer, J. M., Retamar-Gentil, P., Rodríguez-Baño, J., De Cueto, M., Borreguero, I., Nieto Aranda, J., Sousa Domínguez, A., González-Rico, C., Fariñas, M. C., Fernández Ávila, M. L., Romero Palacios, A., Guerrero Sánchez, F. M., Rúa Gómez, M., Bilbao del Olmo, I., Calbo, E., Dietl, B., Ibarguren Pinilla, M., Gómez-Ruiz de Arbulo, M., Torres Beceiro, I., Machuca, I., Cano, Á., Giner Oncina, L., Pinargote Celorio, H., Cendejas, E., Romero Gómez, M., Argüelles Curto, A., Reguero, J. M., Díaz-López, M. D., & Paño, J. R.
- Venue
- The Lancet Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2024-04
- Volume
- 24
- Issue
- 4
- Pages
- 375-385
- ISSN
- 1473-3099 (ISSN-L)
- OpenAlex
- W4390771394
- Cited by
- 38
- References
- 5
- FWCI
- 7.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial. https://app.cochat.ai/papers/10.1016/s1473-3099(23)00686-2
- The paper
- López-Cortés, L. E., Delgado-Valverde, M., Moreno-Mellado, E., Goikoetxea Aguirre, J., Guio Carrión, L., Blanco Vidal, M. J., López Soria, L. M., Pérez-Rodríguez, M. T., Martínez Lamas, L., Arnaiz de las Revillas, F., Armiñanzas, C., Ruiz de Alegría-Puig, C., Jiménez Aguilar, P., del Carmen Martínez-Rubio, M., Sáez-Bejar, C., de las Cuevas, C., Martín-Aspas, A., Galán, F., Yuste, J. R., . . . Paño, J. R. (2024). Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(23)00686-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.